FDA aims to dissuade citizen petition abuse

Factors the US Food and Drug Administration (FDA) will consider in determining whether a citizen petition is submitted with the “primary purpose of delaying the approval of a generic drug application” are described in revised draft guidance that has just been published by the agency, as part of efforts by the FDA to also improve its own review process efficiency.